Journal of Psychopharmacology
December 17, 2024
Gianmarco Ingrosso, Anthony J. Cleare, Mario F Juruena
1 citation
Background: Ketamine has demonstrated both rapid and sustained efficacy in treating depression, especially in treatment-resistant cases. However, concerns regarding the addictive potential of ketamine during long-term depression treatment persist among clinicians. Aim: This review aimed to summarise the evidence on addiction phenomena associated with ketamine treatment of depression. Methods: A...
European Archives of Psychiatry and Clinical Neuroscience
December 16, 2024
Gustavo C. Leal, Isabel Lima-Araújo, David G Roiter et al.
7 citations
Arketamine (R-ketamine), an enantiomer of ketamine, has historically been less studied than esketamine (S-ketamine) and the racemic mixture. Recent preclinical studies suggest that arketamine may offer prolonged antidepressant effects and a superior safety profile. This scoping review aims to assess and synthesise existing literature on the clinical use of arketamine in humans. This review...
Journal of Anesthesia and Translational Medicine
December 1, 2024
Michael S Bodnar, Sierra Barber, Heather S L Jim et al.
3 citations
Depression and pain are common comorbidities in cancer patients, and ketamine, a dissociative anesthetic, has shown potential in managing both. This review summarizes current literature on ketamine and its enantiomer, esketamine, in managing depression and pain in the oncologic population. Studies indicate that sub-anesthetic doses of intravenous ketamine and esketamine can alleviate...
Asian Journal of Psychiatry
December 1, 2024
Hitesh Kumar Behera, Ramesh Joga, Sravani Yerram et al.
Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential, mechanisms, and regulatory...
Molecular Psychiatry
November 29, 2024
Adrian Hase, Gregor Hasler, Abigail E. Calder
12 citations
Abstract Background Peripheral levels of brain-derived neurotrophic factor (BDNF) are often used as a biomarker for the rapid plasticity-promoting effects of ketamine, psychedelics, and other psychoplastogens in humans. However, studies analyzing peripheral BDNF after psychoplastogen exposure show mixed results. In this meta-analysis, we aimed to test whether the rapid upregulation of...
Фармакология & Фармакотерапия
November 6, 2024
Холикназаров А.а., Ямпольская Е.к., Ишеков Н. С.
Более 60 лет назад во врачебной практике появились первые препараты для лечения депрессии. В 1961 г. F. Ayd применил амитриптилин в больнице Франклин-Сквер в Балтиморе (США) и установил его антидепрессивную активность. Затем данная сфера начала бурно развиваться и появилось значительное количество новых антидепрессантов, но они не компенсировали недостатки первых представителей группы –...
CNS Drugs
November 1, 2024
Roger S McIntyre, Rakesh Jain
58 citations
Major depressive disorder (MDD) is a chronic, burdensome, highly prevalent disease that is characterized by depressed mood and anhedonia. MDD is especially burdensome as approved monoamine antidepressant treatments have weeks-long delays before clinical benefit and low remission rates. In the past 2 decades, a promising target emerged to improve patient outcomes in depression treatment:...
Molecular Pharmacology
October 17, 2024
Ivone Gomes, Achla Gupta, Elyssa B Margolis et al.
21 citations
Ketamine is a glutamate receptor antagonist that was developed over 50 years ago as an anesthetic agent. At subanesthetic doses, ketamine and some metabolites are analgesics and fast-acting antidepressants, presumably through targets other than glutamate receptors. We tested ketamine and its metabolites for activity as allosteric modulators of opioid receptors expressed as recombinant receptors...
Psychiatry Research
October 1, 2024
Je-Yeon Yun, Yong‐Ku Kim
11 citations
Treatment-resistant depression (TRD) is defined as patients diagnosed with depression having a history of failure with different antidepressants with an adequate dosage and treatment duration. The NMDA receptor antagonist ketamine rapidly reduces depressive symptoms in TRD. We examined neural correlates of treatment response to ketamine in TRD through a systematic review of brain magnetic...
The International Journal of Neuropsychopharmacology
October 1, 2024
Gargi Mandal, Madeline Kirkpatrick, Silvia Alboni et al.
12 citations
Understanding the precise mechanisms of ketamine is crucial for replicating its rapid antidepressant effects without inducing psychomimetic changes. Here, we explore whether the antidepressant-like effects of ketamine enantiomers are underscored by protection against cytokine-induced reductions in hippocampal neurogenesis and activation of the neurotoxic kynurenine pathway in our...